CD4+ Count–Guided Interruption of Antiretroviral Treatment
暂无分享,去创建一个
[1] J. Neaton,et al. Considerations in choice of a clinical endpoint for AIDS clinical trials. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). , 1994, Statistics in medicine.
[2] A. Mocroft,et al. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? , 2005, AIDS.
[3] J. Lisziewicz,et al. Structured treatment interruptions for the management of HIV infection. , 2001, JAMA.
[4] P. Morlat,et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. , 2004, International journal of epidemiology.
[5] P. Kissinger,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.
[6] V. Soriano,et al. Liver toxicity caused by nevirapine. , 2002, AIDS.
[7] J Darbyshire,et al. CD4+ count-guided interruption of antiretroviral treatment. , 2006, The New England journal of medicine.
[8] JD Lundgren,et al. Changing patterns of mortality across Europe in patients infected with HIV-1 , 1998, The Lancet.
[9] Alan S. Perelson,et al. Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.
[10] Matthias Cavassini,et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial , 2006, The Lancet.
[11] R. Byers,et al. Trends in Diseases Reported on U.S. Death Certificates That Mentioned HIV Infection, 1987‐1999 , 2002, Journal of acquired immune deficiency syndromes.
[12] D. Cooper,et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study , 1999, The Lancet.
[13] J. Currier,et al. Getting smarter--the toxicity of undertreated HIV infection. , 2006, The New England journal of medicine.
[14] J. Bartlett. Combination antiretroviral therapy and the risk of myocardial infarction , 2004 .
[15] A. Mocroft,et al. AIDS across Europe, 1994–98: the EuroSIDA study , 2000, The Lancet.
[16] R. Hogg,et al. To stop or not to stop: that is the question, but what is the answer? , 2002, AIDS.
[17] J. Lisziewicz,et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.
[18] D. Cooper,et al. Adverse effects of antiretroviral therapy , 2000, The Lancet.
[19] F. Clavel,et al. HIV Drug Resistance , 2000, The New England journal of medicine.
[20] B. Hirschel,et al. UvA-DARE ( Digital Academic Repository ) A prospective , randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection , 2005 .
[21] Roger Salamon,et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial , 2006, The Lancet.
[22] J. Margolick,et al. Virologic and immunologic values allowing safe deferral of antiretroviral therapy , 2002, AIDS.
[23] R J Prineas,et al. A new epidemiologic classification system for interim myocardial infarction from serial electrocardiographic changes. , 1989, The American journal of cardiology.
[24] P. O'Brien,et al. A multiple testing procedure for clinical trials. , 1979, Biometrics.
[25] B. Hirschel,et al. Highly Active Antiretroviral Therapy (HAART) Retreatment in Patients on CD4-Guided Therapy Achieved Similar Virologic Suppression Compared With Patients on Continuous HAART: The HIV Netherlands Australia Thailand Research Collaboration 001.4 Study , 2005, Journal of acquired immune deficiency syndromes.
[26] Laurence L. George,et al. The Statistical Analysis of Failure Time Data , 2003, Technometrics.
[27] Mark R Wallace,et al. Comparisons of Causes of Death and Mortality Rates Among HIV-Infected Persons: Analysis of the Pre-, Early, and Late HAART (Highly Active Antiretroviral Therapy) Eras , 2006, Journal of acquired immune deficiency syndromes.
[28] Annapaola Callegaro,et al. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial , 2004, AIDS.
[29] P J Hannan,et al. Prognostic associations of Minnesota Code serial electrocardiographic change classification with coronary heart disease mortality in the Multiple Risk Factor Intervention Trial. , 1997, The American journal of cardiology.
[30] J. Sterne,et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. , 2005, Archives of internal medicine.
[31] G. Lüchters,et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection , 2003, The Lancet.
[32] K. K. Lan,et al. Discrete sequential boundaries for clinical trials , 1983 .
[33] K. Tashima,et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[34] O. Kirk,et al. Cardio- and cerebrovascular events in HIV-infected persons , 2004, AIDS.
[35] Ronald J. Prineas,et al. The Minnesota Code Manual of Electrocardiographic Findings , 2009 .
[36] T. Chun,et al. Latent reservoirs of HIV: obstacles to the eradication of virus. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[37] J H Shih,et al. Sample size calculation for complex clinical trials with survival endpoints. , 1995, Controlled clinical trials.